Ambroxol, a known active-site-directed PC (20, 43, 66) currently being evaluated in a multicenter Phase 3A clinical trial for patients with PD and known GBA1 status (NCT05778617), was identified as a highly active compound in the unbiased primary screen. The gene discussed is GBA1; the disease is Parkinson disease.